Showing 361-370 of 756 results for "".
Therapeutics Focus: Fungal Infections
https://practicaldermatology.com/topics/practice-management/therapeutics-focus-fungal-infections/21184/Raising Issues with MOC
https://practicaldermatology.com/topics/practice-management/raising-issues-with-moc/21195/Dermatologists and the AAD speak out against current MOC requirements and suggest changes.The Melanoma Pipeline
https://practicaldermatology.com/topics/skin-cancer-photoprotection/the-melanoma-pipeline/21400/A closer look at the latest data for two investigational agents that have made headlines.Weighing the Prospects of Biosimilars
https://practicaldermatology.com/columns/clinical-focus-1/weighing-the-prospects-of-biosimilars/21477/If they are found to be comparable to the “originators,” biosimilar agents may offer patients significant therapeutic benefits as well as cost efficiency.EHR User Series—Part III
https://practicaldermatology.com/topics/practice-management/ehr-user-seriespart-iii/21509/A Q&A series with clinicians about their experience and broader impressions of EHRs in dermatology.Looking Under the Hijab: Hair Loss and Cultural Competency
https://practicaldermatology.com/topics/hair-nails/looking-under-the-hijab-hair-loss-and-cultural-competency/67263/The rise of Muslim patients in the U.S. will require dermatologists to become more culturally aware.Staphylococcus aureus Accessory Gene Regulator Quorum-sensing System Inhibits Keratinocyte Lipid Enzymes and Delays Wound Repair
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/staphylococcus-aureus-accessory-gene-regulator-quorum-sensing-system-inhibits-keratinocyte-lipid-enzymes-and-delays-wound-repair/67354/Therapies aimed at inhibiting agr quorum sensing could be a novel strategy to improve healing outcomes.A Bold New Future for Psoriatic Arthritis Treatments in Dermatology
https://practicaldermatology.com/topics/psoriasis/a-bold-new-future-for-psoriatic-arthritis-treatments-in-dermatology/60989/The current therapeutic landscape highlights the dermatologist’s role in PsA management.Advanced Management Solutions for High-Grade Cutaneous Toxicities to Cancer Therapy
https://practicaldermatology.com/topics/skin-cancer-photoprotection/advanced-management-solutions-for-high-grade-cutaneous-toxicities-to-cancer-therapy/57176/The emergence of immune checkpoint inhibitors (ICIs) has fundamentally altered the prognosis for patients with advanced skin malignancies, yet the high incidence of cutaneous immune-related adverse events (irAEs) remains a significant barrier to treatment continuity. Here, we review the clinical manThe State of Prevention in Atopic Dermatitis
https://practicaldermatology.com/topics/atopic-dermatitis/the-state-of-prevention-in-atopic-dermatitis/23183/